TYCC
FATE icon

Texas Yale Capital Corp’s Fate Therapeutics FATE Stock Holding History

Texas Yale Capital Corp’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,000
Closed -$234K – 476
2021
Q4 		$234K Hold
4,000
– – 0.01% 410
2021
Q3 		$237K Hold
4,000
– – 0.01% 408
2021
Q2 		$347K Hold
4,000
– – 0.02% 359
2021
Q1 		$330K Hold
4,000
– – 0.02% 355
2020
Q4 		$364K Buy
+4,000
New +$248K 0.02% 343

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Texas Yale Capital Corp's FATE Position: Q1 2022 in Review

Texas Yale Capital Corp sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 4,000 shares — an estimated $234K sold.

Texas Yale Capital Corp first reported a position in FATE in Q4 2020 and held it in 5 quarters. The position peaked at $364K in Q4 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Texas Yale Capital Corp reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Texas Yale Capital Corp sold 4,000 Fate Therapeutics shares in Q1 2022, an estimated $234K.
  • Texas Yale Capital Corp first reported a position in Fate Therapeutics in Q4 2020 and held it in 5 quarters.
  • Texas Yale Capital Corp's Fate Therapeutics position peaked at $364K in Q4 2020.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Texas Yale Capital Corp's 13F filing for Q1 2022, filed 10 May 2022.